MX9203231A - Derivados de tetrahidropiprrol[1,2-a]pirazina-4-spiro-3'-pirrolidina, proceso para su obtencion y composicion farmaceutica que los contiene - Google Patents

Derivados de tetrahidropiprrol[1,2-a]pirazina-4-spiro-3'-pirrolidina, proceso para su obtencion y composicion farmaceutica que los contiene

Info

Publication number
MX9203231A
MX9203231A MX9203231A MX9203231A MX9203231A MX 9203231 A MX9203231 A MX 9203231A MX 9203231 A MX9203231 A MX 9203231A MX 9203231 A MX9203231 A MX 9203231A MX 9203231 A MX9203231 A MX 9203231A
Authority
MX
Mexico
Prior art keywords
spiro
pharmaceutical composition
carbon atoms
derivatives
tetrahidropiprrol
Prior art date
Application number
MX9203231A
Other languages
English (en)
Inventor
Toshiyuki Negoro
Makoto Murata
Shozo Ueda
Buichi Fujitani
Yoshiyuki Ono
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of MX9203231A publication Critical patent/MX9203231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La invención se refiere a los derivados de tetrahidropirrolo[1, 2-a]piracina-4-espiro-3'-pirrolidina y sus sales farmacéuticamente aceptables, los procesos para su preparación y la composición farmacéuticamente aceptable, los procesos para su preparación y la composición farmacéutica que los contiene. Dichos compuestos y sus sales muestran excelente actividad inhibitoria de la enzima aldosa-reductasa y es útil para la prevención de las complicaciones diabéticas.
MX9203231A 1991-06-26 1992-06-24 Derivados de tetrahidropiprrol[1,2-a]pirazina-4-spiro-3'-pirrolidina, proceso para su obtencion y composicion farmaceutica que los contiene MX9203231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03183185 1991-06-26

Publications (1)

Publication Number Publication Date
MX9203231A true MX9203231A (es) 1993-08-01

Family

ID=16131263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203231A MX9203231A (es) 1991-06-26 1992-06-24 Derivados de tetrahidropiprrol[1,2-a]pirazina-4-spiro-3'-pirrolidina, proceso para su obtencion y composicion farmaceutica que los contiene

Country Status (21)

Country Link
US (1) US5258382A (es)
EP (1) EP0520320B1 (es)
JP (1) JP2516147B2 (es)
KR (1) KR100241196B1 (es)
CN (1) CN1034176C (es)
AT (1) ATE157980T1 (es)
AU (1) AU648901B2 (es)
CA (1) CA2071273C (es)
DE (1) DE69222096T2 (es)
DK (1) DK0520320T3 (es)
ES (1) ES2108717T3 (es)
FI (1) FI98066C (es)
GR (1) GR3024870T3 (es)
HK (1) HK1001728A1 (es)
HU (1) HU218214B (es)
IE (1) IE921891A1 (es)
MX (1) MX9203231A (es)
NO (1) NO300637B1 (es)
NZ (1) NZ243255A (es)
TW (1) TW202450B (es)
ZA (1) ZA924425B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3195455B2 (ja) * 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
JP3681082B2 (ja) * 1996-06-27 2005-08-10 住友ベークライト株式会社 イミド環含有エポキシ樹脂及びエポキシ樹脂組成物
DE69830333T2 (de) * 1997-10-20 2006-01-26 Dainippon Pharmaceutical Co., Ltd. SCHNELLÖSLICHE ARZNEIMITTELZUSAMMENSETZUNG ENTHALTEND MIKRONISiERTE AS-3201
JP2007246539A (ja) * 1997-10-20 2007-09-27 Dainippon Sumitomo Pharma Co Ltd 速溶性医薬組成物
CN1152686C (zh) * 1997-10-20 2004-06-09 大日本制药株式会社 稳定化药用组合物
WO2001034148A1 (fr) * 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Preparations solides pour administration orale
ATE319712T1 (de) 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
JP4552189B2 (ja) * 2002-11-14 2010-09-29 小野薬品工業株式会社 脊柱管狭窄症治療剤
US8003808B2 (en) * 2006-07-07 2011-08-23 Dainippon Sumitomo Pharma Co., Ltd. 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same
EP2058300B1 (en) * 2006-08-31 2013-01-09 Dainippon Sumitomo Pharma Co., Ltd. Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation
WO2008035735A1 (fr) 2006-09-20 2008-03-27 Nissan Chemical Industries, Ltd. Procédé de production d'un composé de succinimide optiquement actif
CN101516843B (zh) * 2006-09-27 2011-06-15 日产化学工业株式会社 琥珀酰亚胺化合物的制造方法
US20110190497A1 (en) * 2006-09-29 2011-08-04 Daisuke Tanaka Process for production of 2,5 dioxopyrrolidine 3 carboxylate
WO2008050847A1 (fr) 2006-10-25 2008-05-02 Dainippon Sumitomo Pharma Co., Ltd. Préparation granulaire non agglutinante
JPWO2008081860A1 (ja) * 2006-12-28 2010-04-30 大日本住友製薬株式会社 光学活性コハク酸イミド誘導体およびその製造方法ならびにその使用
WO2008136527A1 (ja) * 2007-05-08 2008-11-13 Dainippon Sumitomo Pharma Co., Ltd. 光学活性ジオキソピロリジン誘導体の精製方法
EP2164488A1 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain
JP2011026201A (ja) * 2007-10-17 2011-02-10 Mitsubishi Tanabe Pharma Corp 光学活性ピロリル−コハク酸イミド誘導体の立体選択的な製造方法
JP5697998B2 (ja) 2009-02-06 2015-04-08 大日本住友製薬株式会社 光学活性スクシンイミド誘導体の製造方法及びその中間体
WO2012014953A1 (ja) 2010-07-29 2012-02-02 大日本住友製薬株式会社 光学活性スクシンイミド誘導体の製造方法
EP2671589A4 (en) 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICINAL AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMABILITY
US10034880B2 (en) * 2014-09-11 2018-07-31 Sumitomo Dainippon Pharma Co., Ltd. Ophthalmic suspension formulation
CN106928234A (zh) * 2017-02-07 2017-07-07 上海合全药业股份有限公司 （2‑苄基‑1,2,3,4‑四氢吡咯并[1,2‑a]吡嗪）‑4‑甲醇的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142984A (ja) * 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4656169A (en) * 1984-08-14 1987-04-07 Pfizer Inc. Tetracyclic spiro-hydantoin aldose reductase inhibitors and compositions
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors

Also Published As

Publication number Publication date
CA2071273A1 (en) 1992-12-27
FI922848A0 (fi) 1992-06-18
JPH05186472A (ja) 1993-07-27
EP0520320B1 (en) 1997-09-10
FI98066C (fi) 1997-04-10
NO922512L (no) 1992-12-28
EP0520320A3 (en) 1993-03-24
AU648901B2 (en) 1994-05-05
CN1034176C (zh) 1997-03-05
ZA924425B (en) 1993-03-31
ES2108717T3 (es) 1998-01-01
KR100241196B1 (ko) 2000-03-02
NZ243255A (en) 1994-03-25
DE69222096D1 (de) 1997-10-16
DE69222096T2 (de) 1998-01-22
US5258382A (en) 1993-11-02
DK0520320T3 (da) 1997-10-13
IE921891A1 (en) 1992-12-30
AU1848392A (en) 1993-01-14
HU9202105D0 (en) 1992-10-28
CA2071273C (en) 2002-08-20
NO300637B1 (no) 1997-06-30
TW202450B (es) 1993-03-21
GR3024870T3 (en) 1998-01-30
KR930000519A (ko) 1993-01-15
HU218214B (hu) 2000-06-28
FI98066B (fi) 1996-12-31
EP0520320A2 (en) 1992-12-30
ATE157980T1 (de) 1997-09-15
FI922848A (fi) 1992-12-27
HUT63424A (en) 1993-08-30
HK1001728A1 (en) 1998-07-03
CN1068825A (zh) 1993-02-10
JP2516147B2 (ja) 1996-07-10
NO922512D0 (no) 1992-06-25

Similar Documents

Publication Publication Date Title
MX9203231A (es) Derivados de tetrahidropiprrol[1,2-a]pirazina-4-spiro-3'-pirrolidina, proceso para su obtencion y composicion farmaceutica que los contiene
PT79819B (en) Process to prepare dihydropiridazinone derivatives its salts and pharmaceutical compositions and intermediate compounds there with
TW377352B (en) Pyrido[2,3-d]pyrimidine derivatives and pharmaceutical compositions thereof
ES2100861T3 (es) Composiciones farmaceuticas para la inhibicion de la reaccion de maillard.
AU626740B2 (en) Aminocarbonylcarbamates related to physostigmine, a process for their preparation and their use as medicaments
CA2042113A1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
RU95101437A (ru) Содержащее производные 3-фенилсульфонил-3,7-диазабицикло [3,3,1] нонана лекарственное средство, способ получения производных 3-фенилсульфонил-3,7-диазабицикло-[3,3,1]-нонана
CA2042112A1 (en) N'-alkyl-spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
FI942401A (fi) 1'-amino-2-/(bentsotiatsolyyli)metyyli/spiro/isokinoliini-4(1H), 3'-pyrrolidiini/-1,2',3,5'(2H)-tetronit ja niiden analogit, jotka ovat käyttökelpoisia aldoosireduktaasin estäjinä